Fiche centre
University of North Carolina at Chapel Hill
Chapel Hill — United States
Essais liés18clinical trials
VilleChapel Hilllocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06667908
Essais cliniques associés
18| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| VS-7375 | Cancer | Phase 2 | NCT07659782 | TARGET-D 202 — A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | RECRUITING |
| Colchicine 0.5 MG Oral Tablet | Maladie coronarienne | Phase 3 | NCT04774159 | LEADER-PAD — Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | RECRUITING |
| Sirolimus | Épilepsie | Phase 2 | NCT05104983 | TSC-STEPS — Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | ACTIVE_NOT_RECRUITING |
| JNJ-90301900 | Cancer | Phase 2 | NCT06667908 | CONVERGE — A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) | RECRUITING |
| S-Cone Stimulating Chromatic Light | Myopathies | Non applicable | NCT07825792 | Light Bulb Stimuli to Reduce Chronic Pain | NOT_YET_RECRUITING |
| Mycophenolate Mofetil | Lupus | Phase 2 | NCT05538208 | The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study | RECRUITING |
| Low Dose Mesenchymal Stem Cells (MSCs) | Lupus | Phase 2 | NCT02633163 | Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) | COMPLETED |
| Direct cortical stimulation (DCS) Alpha | Épilepsie | Non applicable | NCT06252532 | Causal Role of Top-Down Theta Oscillations in Prioritization | ENROLLING_BY_INVITATION |
| Omega-3 Supplementation for Pediatric Migraine | Migraine | Non applicable | NCT06899074 | Omega-3 Supplementation for Pediatric Migraine | COMPLETED |
| ADAPT — Marine Lipids Ease Painful TMD | Migraine | Non applicable | NCT07437313 | ADAPT — Marine Lipids Ease Painful TMD | NOT_YET_RECRUITING |
| 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | Migraine | Phase 2 | NCT03844412 | Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments | COMPLETED |
| RE104 for Injection | Sclérose latérale amyotrophique | Phase 2 | NCT07002034 | RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | RECRUITING |
| Mycophenolate Mofetil | Myasthénie | À vérifier | NCT03490539 | PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis | COMPLETED |
| Litifilimab | Lupus | Phase 2/3 | NCT05531565 | AMETHYST — A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| zorevunersen | Épilepsie | Phase 3 | NCT06872125 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | ACTIVE_NOT_RECRUITING |
| Efgartigimod IV | Myasthénie | Phase 2/3 | NCT04833894 | ADAPT Jr — Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| eculizumab | Myasthénie | Phase 2 | NCT00727194 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis | TERMINATED |